NASDAQ:EYESSecond Sight Medical Products Stock Price, Forecast & News

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EYES shares have decreased by 74.4% and is now trading at $0.9050. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products.

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Second Sight Medical Products.

Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings data on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.16. Second Sight Medical Products had a negative return on equity of 308.26% and a negative net margin of 994.14%. View Second Sight Medical Products' earnings history.

2 equities research analysts have issued 12-month target prices for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.25 in the next twelve months. This suggests a possible upside of 148.6% from the stock's current price. View analysts' price targets for Second Sight Medical Products.

News articles about EYES stock have trended negative on Thursday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Second Sight Medical Products.

Second Sight Medical Products saw a drop in short interest in June. As of June 30th, there was short interest totaling 628,700 shares, a drop of 11.2% from the June 15th total of 708,200 shares. Based on an average daily volume of 947,100 shares, the days-to-cover ratio is presently 0.7 days. Currently, 5.0% of the shares of the stock are sold short. View Second Sight Medical Products' Current Options Chain.

Some companies that are related to Second Sight Medical Products include Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR), IRIDEX (IRIX), CHF Solutions (CHFS), Helius Medical Technologies (HSDT), Precision Optics (PEYE), Reshape Lifesciences (RSLS), Digirad (DRAD), ENDRA Life Sciences (NDRA), Viveve Medical (VIVE), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD) and Magna-Lab (MAGAA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Canopy Growth (CGC), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP), TransEnterix (TRXC) and Plug Power (PLUG).

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $0.91.

Second Sight Medical Products has a market capitalization of $20.92 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

The official website for Second Sight Medical Products is www.secondsight.com.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]